HarNeedi - Healthcare & Pharma Job Portal

The Indian pharmaceuticals market increased at a Compound Annual Growth Rate (CAGR) of 17.46 % in 2015 from US$ 6 billion in 2005 and is expected to expand at a CAGR of 15.92 % to US$ 55 billion by 2020. In terms of world standings, the domestic pharmaceutical industry stands 4th in terms of volume and 13th in value terms. The higher-ranking in value terms could also be musing of the low prices at which medicines are sold in the country. According to the IBEF report, “By 2020, India is likely to be among the top 3 pharmaceutical markets by incremental growth and 6th largest market globally in absolute size”, also highly organized sector, a number of medicine companies promoting their operations in India. Biopharma companies have built up Good Manufacturing Practices (GMP) compliant facilities for the manufacture of different dosage forms. In addition to having GMP, WHO, several Indian companies have also been obtaining plant approvals from international regulatory agencies like US ...

The Indian pharmaceuticals market increased at a Compound Annual Growth Rate (CAGR) of 17.46 % in 2015 from US$ 6 billion in 2005 and is expected to expand at a CAGR of 15.92 % to US$ 55 billion by 2020. The drug industry has various things going in its favour such as low manufacturing cost connected with strong policy initiations from the Indian government. The government of India brought out “Pharma Vision 2020” with an intention to make India one of the top 5 drug innovation centres by 2020. Also the government of India aims to endure the drug industry by foremost infrastructure, scientific workforce for drug research and development, venture investment for pharmaceutical research and several tax benefits. To make better or  more attractive and move gently drug business in India , the clearance timelines for the new manufacturing facilities has been significantly cut down. The government has also permitted foreign direct investments (FDI) under the automatic path in drug s...